TNLIPTN-20

Description

TNLIPTN-20 contains Teneligliptin 20 mg in tablet form. Teneligliptin is an oral antidiabetic medicine belonging to the DPP-4 inhibitor class. It helps improve blood glucose control in adults with type 2 diabetes mellitus by enhancing glucose-dependent insulin release and reducing glucagon activity. TNLIPTN-20 may be prescribed alongside appropriate diet and exercise when additional blood glucose control is required.

For related diabetic and cardiovascular formulations, explore the Medhexa Pharma Cardries Biotic range for additional pharmaceutical products and business enquiries.

Therapeutic Segment

Anti-Diabetic Therapy | Type 2 Diabetes Management | DPP-4 Inhibitors | Blood Glucose Control

Uses of TNLIPTN-20

TNLIPTN-20 may be prescribed as part of an individualized treatment plan for:

• Type 2 diabetes mellitus
• Inadequate blood glucose control with diet and exercise alone
• Patients requiring DPP-4 inhibitor therapy
• Improving glycaemic control when additional oral antidiabetic treatment is required
• Combination therapy with other antidiabetic medicines when clinically appropriate

Teneligliptin is intended for type 2 diabetes management and should be used according to the healthcare professional’s advice. It is not intended for the treatment of type 1 diabetes or diabetic ketoacidosis.

Key Benefits of TNLIPTN-20

• Blood glucose support: Helps improve glycaemic control in adults with type 2 diabetes.
• DPP-4 inhibitor: Teneligliptin works by inhibiting the DPP-4 enzyme involved in incretin hormone breakdown.
• Glucose-dependent action: Supports insulin release particularly when blood glucose levels are elevated.
• Helps regulate glucagon: Can reduce inappropriate glucagon secretion following meals.
• Convenient oral formulation: Supplied as a 20 mg tablet.
• Suitable for individualized therapy: May be used alone or alongside other diabetes medicines when prescribed.

How TNLIPTN-20 Works

Teneligliptin belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class.

After meals, the body releases incretin hormones such as GLP-1 and GIP. These hormones help the pancreas release insulin when blood glucose rises and can reduce glucagon secretion.

DPP-4 normally breaks down these incretin hormones. By inhibiting DPP-4, teneligliptin helps prolong incretin activity. Consequently, it supports glucose-dependent insulin secretion and helps reduce excessive glucagon activity.

Through these complementary effects, TNLIPTN-20 can help improve blood glucose levels in adults with type 2 diabetes when used as part of an appropriate treatment plan.

Common Side Effects of TNLIPTN-20

Teneligliptin is generally tolerated by many patients, although side effects can occur. Possible effects include:

• Nausea
• Diarrhoea
• Constipation
• Abdominal discomfort
• Headache
• Dizziness
• Skin rash
• Hypoglycaemia, particularly when used with insulin or sulfonylureas

When TNLIPTN-20 is combined with other medicines that can cause low blood sugar, the risk of hypoglycaemia may increase.

Seek medical attention if you experience severe or persistent abdominal pain, significant allergic symptoms, breathing difficulty, swelling or symptoms of severe hypoglycaemia.

Important Safety Information

Use TNLIPTN-20 only according to the advice of a qualified healthcare professional.

• TNLIPTN-20 is intended for type 2 diabetes mellitus and should not be used to treat type 1 diabetes or diabetic ketoacidosis.
• Monitor blood glucose as recommended by your diabetes-care team.
• The risk of hypoglycaemia can increase when teneligliptin is used with insulin or sulfonylurea medicines. Your healthcare professional may adjust the treatment regimen when necessary.
• Tell your doctor if you have a history of pancreatitis. Seek medical attention if you develop persistent, severe abdominal pain, especially if it radiates to the back.
• Inform your healthcare professional if you have kidney or liver disease so that treatment can be assessed appropriately.
• Tell your doctor about all prescription medicines, over-the-counter medicines, vitamins and supplements you take.
• Report symptoms of an allergic reaction, including severe rash, facial or throat swelling or breathing difficulty.
• Do not change the dose or stop diabetes treatment without medical advice.
• Continue appropriate diet, physical activity and blood glucose monitoring as recommended.
• Discuss pregnancy or breastfeeding with your healthcare professional before using teneligliptin.
• Keep the medicine out of the reach of children.

For additional information about teneligliptin and its use in diabetes management, refer to the Indian Council of Medical Research (ICMR) diabetes resources and the approved prescribing information applicable to the product.

Dosage & Administration

Take TNLIPTN-20 exactly as prescribed by your healthcare professional.

The appropriate dose depends on the patient’s blood glucose control, current diabetes treatment, kidney and liver function, tolerability and the approved product information applicable to the market.

For teneligliptin, 20 mg once daily is a commonly used adult dose in Indian prescribing practice. However, the appropriate regimen may vary according to the individual patient and accompanying antidiabetic medicines.

TNLIPTN-20 may generally be taken with or without food unless the product information or healthcare professional advises otherwise.

Swallow the tablet with water. Do not increase the dose, take additional tablets or discontinue treatment without medical advice.

If you miss a dose, follow your healthcare professional’s instructions. Do not take a double dose to compensate for a missed tablet.

Storage

• Store TNLIPTN-20 in a cool, dry place.
• Protect the tablets from excessive heat and moisture.
• Keep the tablets away from direct sunlight.
• Keep the tablets in their original ALU-ALU packaging until use.
• Keep out of the sight and reach of children.
• Do not use the product after the expiry date printed on the packaging.